PainReform Ltd. (PRFX) Balance Sheet

NASDAQ: PRFXAssets, liabilities, debt and equity over 9 years.

PRFX balance sheet, 2025

December 31, 2025 · U.S. dollars

$12.0M assets = $2.7M liabilities + $9.3M equity

What it owns$12.0MCash & ST investments: $4.2M (34.7%)Cash & ST investments$4.2M · 35%Receivables: $142,000 (1.2%)Other current: $43,000 (0.4%)PP&E: $56,000 (0.5%)Goodwill & intangibles: $7.8M (64.8%)Goodwill & intangibles$7.8M · 65%=How it is financed$12.0MCurrent liabilities: $2.4M (20.3%)Current liabilities$2.4M · 20%Other LT liabilities: $267,000 (2.2%)Shareholders’ equity: $9.3M (77.4%)Shareholders’ equity$9.3M · 77%

Both columns are drawn to the same scale: what PRFX owns equals what it owes plus shareholders’ equity. Hover a block for its value.

PRFX financial health

Current ratio1.78
Comfortable · current assets cover current liabilities 1.78×
Debt / equity0.00
Low leverage · $0.00 of debt for each $1 of equity
Equity / assets71.2%
Equity-funded · of assets funded by shareholders
Cash / debt19,838.1%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles64.8%
Mostly intangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

PRFX balance sheet trends, 2017–2025

PainReform Ltd. balance sheet trends
MetricTrendThenLatestChange
Total assets$214,0002017$12.0M2025+65.4%/yr
Total liabilities$3.8M2017$2.7M2025−4.3%/yr
Shareholders’ equity−$3.6M2017$8.5M2025—
Cash & short-term investments$187,0002017$4.2M2025+47.4%/yr
Total debt$3.7M2017$21,0002025−47.6%/yr
Net cash (debt)−$3.5M2017$4.1M2025+$7.7M
Working capital$78,0002017$1.9M2025+$1.8M
Current ratio1.5820171.782025+0.20
Debt / equity0.0120230.002025−0.01

Change is the average annual growth (CAGR) or the difference between the first and latest year.

PRFX assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

PRFX liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

PRFX debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

PRFX balance sheet

PainReform Ltd. annual balance sheet
202520242023202220212020201920182017
Assets
Cash & short-term investments$4.2M$4.3M$8.0M$4.1M$16.5M$15.7M$941,000$40,000$187,000
Cash & equivalents$4.2M$4.3M$8.0M$4.1M$16.5M$15.7M$941,000$40,000$187,000
Short-term investments$1.0M$0$0$6.1M$0————
Receivables$142,000$119,000$45,000$55,000$218,000$53,000$22,000$28,000$20,000
Inventory$0$0$0$7.8M$2.2M$2.0M$6,000$0$0
Other current assets$43,000$48,000$1.7M$310,000$30,000$20,000$3,000$12,000$6,000
Total current assets$4.4M$4.4M$9.8M$12.3M$19.0M$17.8M$972,000$80,000$213,000
Property, plant & equipment (net)$56,000$97,000$131,000$44,000$53,000$10,000$0$1,000$1,000
Goodwill & intangible assets$7.8M$0$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0$0$0
Other non-current assets$0$0$0$0$0$0$192,000$0$0
Total assets$12.0M$4.5M$9.9M$12.3M$19.1M$17.8M$1.2M$81,000$214,000
Liabilities
Accounts payable$213,000$296,000$221,000$209,000$136,000$720,000$22,000$2,000$64,000
Short-term debt$21,000$45,000$56,000———$6.2M——
Total current liabilities$2.4M$2.4M$2.4M$1.1M$757,000$961,000$6.3M$18,000$135,000
Long-term debt$0$0$0$0$0$0$0$4.5M$0
Lease obligations$21,000$45,000$86,000——————
Other long-term liabilities$267,000$259,000$281,000$243,000$234,000$220,000$447,000$0$3.7M
Total liabilities$2.7M$2.7M$2.7M$1.3M$991,000$1.2M$6.8M$4.5M$3.8M
Shareholders' equity
Common stock & paid-in capital——$147,000$94,000$94,000$78,000$5,000$5,000$5,000
Retained earnings (deficit)−$61.3M−$56.5M−$41.9M−$32.5M−$23.7M−$16.5M−$12.4M−$11.1M−$10.3M
Accumulated other comprehensive income$0———$0——$0$0
Minority interest$747,000$0———————
Total shareholders' equity$8.5M$1.8M$7.2M$11.0M$18.1M$16.6M−$5.6M−$4.5M−$3.6M
Key figures
Total debt$21,000$45,000$86,000———$6.2M$4.5M$3.7M
Net cash (debt)$4.1M$4.2M$7.9M———−$5.2M−$4.5M−$3.5M
Working capital$1.9M$2.0M$7.4M$11.2M$18.3M$16.8M−$5.4M$62,000$78,000
Tangible book value$766,000$1.8M$7.2M$11.0M$18.1M$16.6M−$5.6M−$4.5M−$3.6M
Current ratio1.781.814.0711.5525.1318.510.154.441.58
Quick ratio1.761.793.353.9022.1316.370.153.781.53
Debt / equity0.000.020.01——————
Equity / assets71.2%40.3%72.9%89.4%94.8%93.4%−483.0%−5,502.5%−1,695.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 26, 2026); data from EODHD.

PRFX financial position

At the end of fiscal 2025 (December 31, 2025), PainReform had total assets of $12.0 million (up 165.1% from a year earlier), total liabilities of $2.7 million and shareholders' equity of $8.5 million. It held $4.2 million in cash and short-term investments against $0.0 million of debt, a net cash position of $4.1 million. Its current ratio was 1.78. In the latest quarter (ended June 30, 2026) total assets were $19.1 million and equity $15.9 million.

Related: PRFX income statement, PRFX cash flow statement, PRFX key metrics. See the PRFX stock overview for the latest quote and news.

PRFX balance sheet FAQ

What are PainReform's total assets?

PainReform reported total assets of $12.0 million at the end of fiscal 2025 (December 31, 2025), compared with $4.5 million a year earlier.

How much debt does PainReform have?

PainReform had $0.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.

How much cash does PainReform have?

PainReform held $4.2 million in cash and short-term investments at the end of fiscal 2025; with $0.0 million of debt that is net cash of $4.1 million.

What is PainReform's book value?

PainReform's shareholders' equity (book value) was $8.5 million at the end of fiscal 2025.

What is PainReform's current ratio?

PainReform had current assets of $4.4 million and current liabilities of $2.4 million, a current ratio of 1.78 (it can cover its short-term obligations).

How much goodwill does PainReform have?

PainReform carried $7.8 million of goodwill and intangible assets, 64.8% of total assets, at the end of fiscal 2025.

Drug Manufacturers - Specialty & Generic: balance sheet